Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 19, 2026, 11:50 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Control Group - Vehicle Safety Clear all
Completed Phase 3 Interventional Results available

Efficacy Safety, and Tolerability of Topical Terbinafine in Patients With Mild to Moderate Toenail Fungus of the Big Toenail

NCT00443820
View directory record Official record
Conditions
Onychomycosis
Interventions
terbinafine, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
12 Years to 75 Years
Enrollment
526 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
20
States / cities
Novato, California • Northglenn, Colorado • Melbourne, Florida + 17 more
Source: ClinicalTrials.gov public record
Updated Apr 18, 2011 · Synced Sep 19, 2026, 11:50 AM EDT
Terminated Phase 2 Interventional

Study of Human Placenta-derived Cells (PDA001) to Evaluate the Safety and Effectiveness for Patients With Active Rheumatoid Arthritis

NCT01261403
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
PDA001, Vehicle Controlled Placebo
Biological · Drug
Lead sponsor
Celularity Incorporated
Industry
Eligibility
18 Years to 75 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
16
States / cities
Anniston, Alabama • Arcadia, California • Los Angeles, California + 12 more
Source: ClinicalTrials.gov public record
Updated Jul 21, 2020 · Synced Sep 19, 2026, 11:50 AM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy Study of DSC127 in Treating Subjects With Diabetic Ulcers

NCT00796744
View directory record Official record
Conditions
Foot Ulcer, Diabetic, Diabetic Foot
Interventions
NorLeu3-A(1-7) in a gel formulation
Drug
Lead sponsor
US Biotest, Inc.
Industry
Eligibility
18 Years and older
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
12
States / cities
Tucson, Arizona • Castro Valley, California • San Diego, California + 8 more
Source: ClinicalTrials.gov public record
Updated Sep 26, 2012 · Synced Sep 19, 2026, 11:50 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of APP13007 for Treatment of Inflammation and Pain After Cataract Surgery Including a Corneal Endothelial Cell Sub-study

NCT04810962
View directory record Official record
Conditions
Ocular Inflammation and Pain After Cataract Surgery
Interventions
APP13007, 0.05%, Matching Vehicle Placebo for APP13007, 0.05%
Drug
Lead sponsor
Formosa Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
370 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
31
States / cities
Chandler, Arizona • Mesa, Arizona • Phoenix, Arizona + 28 more
Source: ClinicalTrials.gov public record
Updated Jul 24, 2023 · Synced Sep 19, 2026, 11:50 AM EDT
Completed Phase 3 Interventional Results available

Topical Ruxolitinib Evaluation in Atopic Dermatitis Study 1 (TRuE AD1) - An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis

NCT03745638
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Ruxolitinib Cream, Vehicle Cream
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
12 Years and older
Enrollment
631 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
42
States / cities
Birmingham, Alabama • Phoenix, Arizona • Fountain Valley, California + 35 more
Source: ClinicalTrials.gov public record
Updated Sep 27, 2023 · Synced Sep 19, 2026, 11:50 AM EDT
Completed Phase 2Phase 3 Interventional

Assessment of the Safety and Efficacy of RGN-259 Ophthalmic Solutions for Dry Eye Syndrome: ARISE-1

NCT02597803
View directory record Official record
Conditions
Dry Eye Syndrome
Interventions
RGN-259, Placebo
Drug
Lead sponsor
ReGenTree, LLC
Industry
Eligibility
18 Years and older
Enrollment
317 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Andover, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 16, 2019 · Synced Sep 19, 2026, 11:50 AM EDT
Completed Phase 3 Interventional Results available

A Safety and Efficacy Study of Dapsone Gel in Patients With Acne Vulgaris

NCT01974141
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Dapsone Gel, Dapsone Gel Vehicle
Drug
Lead sponsor
Almirall, S.A.
Industry
Eligibility
12 Years and older
Enrollment
2,102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Encino, California
Source: ClinicalTrials.gov public record
Updated Oct 8, 2018 · Synced Sep 19, 2026, 11:50 AM EDT
Completed Phase 2 Interventional Results available

A Phase 2, Multicenter, Randomized, Double-Blind, Vehicle Controlled, Parallel-Group, Clinical Study in the Treatment of Acne Vulgaris

NCT03170388
View directory record Official record
Conditions
Acne Vulgaris
Interventions
IDP-126 Gel, IDP-126 Component A, IDP-126 Component B, IDP-126 Component C, IDP-126 Vehicle Gel
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
9 Years to 99 Years
Enrollment
741 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
29
States / cities
Hot Springs, Arkansas • Fremont, California • Sacramento, California + 24 more
Source: ClinicalTrials.gov public record
Updated Nov 9, 2021 · Synced Sep 19, 2026, 11:50 AM EDT
Completed Phase 2 Interventional

Safety and Efficacy Study of SJP-0035 Ophthalmic Solution in Patients With Moderate to Severe Corneal Epithelial Disorders

NCT02104388
View directory record Official record
Conditions
Corneal Epithelial Disorders
Interventions
SJP-0035 Ophthalmic Solution, Vehicle of SJP-0035 Ophthalmic Solution
Drug
Lead sponsor
Senju Pharmaceutical Co., Ltd.
Industry
Eligibility
18 Years to 75 Years
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
17
States / cities
Little Rock, Arkansas • Glendale, California • Glendora, California + 14 more
Source: ClinicalTrials.gov public record
Updated Mar 28, 2021 · Synced Sep 19, 2026, 11:50 AM EDT
Completed Phase 3 Interventional

Safety and Efficacy of OMS103HP-S Administered in Joint Irrigation Solution to Subjects Undergoing Arthroscopic Meniscectomy

NCT01406561
View directory record Official record
Conditions
Meniscal Tear
Interventions
OMS103HP-S, Vehicle
Drug
Lead sponsor
Omeros Corporation
Industry
Eligibility
18 Years to 75 Years
Enrollment
344 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
18
States / cities
Phoenix, Arizona • Tucson, Arizona • Encinitas, California + 14 more
Source: ClinicalTrials.gov public record
Updated Oct 25, 2018 · Synced Sep 19, 2026, 11:50 AM EDT
Completed Phase 3 Interventional Results available

Clinical Study Comparing the Efficacy and Safety of IDP-126 Gel in the Treatment of Acne Vulgaris

NCT04214652
View directory record Official record
Conditions
Acne Vulgaris
Interventions
IDP-126 Gel, IDP-126 Vehicle Gel
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
9 Years and older
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
10
States / cities
Rogers, Arkansas • Manhattan Beach, California • West Palm Beach, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Jan 31, 2024 · Synced Sep 19, 2026, 11:50 AM EDT
Completed Phase 1Phase 2 Interventional Results available

A Study to Evaluate the Safety and Efficacy of EV06 Ophthalmic Solution in Improving Vision in Subjects With Presbyopia

NCT02516306
View directory record Official record
Conditions
Presbyopia
Interventions
EV06 Ophthalmic Solution, Placebo Ophthalmic Solution
Drug
Lead sponsor
Encore Vision, Inc.
Industry
Eligibility
45 Years to 55 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
4
States / cities
Artesia, California • Mission Hills, California • Washington, Missouri + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 1, 2018 · Synced Sep 19, 2026, 11:50 AM EDT
Completed Phase 2 Interventional

DMT210 Topical Gel in the Treatment of Acne Rosacea

NCT03003104
View directory record Official record
Conditions
Acne Rosacea
Interventions
DMT210 Topical Gel 5%, Vehicle Control
Drug · Other
Lead sponsor
Dermata Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
107 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
9
States / cities
San Diego, California • Miami, Florida • Fridley, Minnesota + 6 more
Source: ClinicalTrials.gov public record
Updated Apr 17, 2018 · Synced Sep 19, 2026, 11:50 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AKB-9778 Ophthalmic Solution

NCT04284514
View directory record Official record
Conditions
Ocular Hypertension, Primary Open Angle Glaucoma
Interventions
AKB-9778 Ophthalmic Solution, Placebo Ophthalmic Solution
Drug
Lead sponsor
Aerpio Therapeutics
Industry
Eligibility
18 Years to 70 Years
Enrollment
91 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
2
States / cities
Austin, Texas • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Feb 24, 2020 · Synced Sep 19, 2026, 11:50 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Human Repeated Insult Patch Test (HRIPT) of Azelaic Acid Pre Foam Formulation

NCT01430533
View directory record Official record
Conditions
Healthy
Interventions
azelaic acid pre foam formulation, Vehicle pre foam formulation, Water
Drug
Lead sponsor
LEO Pharma
Industry
Eligibility
18 Years to 65 Years
Enrollment
240 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Fargo, North Dakota
Source: ClinicalTrials.gov public record
Updated Mar 31, 2020 · Synced Sep 19, 2026, 11:50 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

A Trial to Assess the Effect of Delgocitinib Cream 20 mg/g on the Molecular Signature, Safety, and Efficacy in Adults With Frontal Fibrosing Alopecia

NCT05332366
View directory record Official record
Conditions
Frontal Fibrosing Alopecia
Interventions
Delgocitinib cream, Delgocitinib cream vehicle
Drug
Lead sponsor
LEO Pharma
Industry
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Burlington, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 5, 2025 · Synced Sep 19, 2026, 11:50 AM EDT
Completed Phase 2 Interventional Results available

A Phase IIb Safety and Efficacy Study of DE-126 Ophthalmic Solution in Primary Open-Angle Glaucoma or Ocular Hypertension- Angel Study

NCT03216902
View directory record Official record
Conditions
Open-angle Glaucoma, Ocular Hypertension
Interventions
Vehicle of DE-126 Ophthalmic Solution, high dose of DE-126 Ophthalmic Solution, Topical ultra-low dose of DE-126 Ophthalmic Solution, Topical low dose of DE-126 Ophthalmic Solution, Topical medium dose of DE-126 Ophthalmic Solution, Topical high dose of DE-126 Ophthalmic Solution, 0.005% Latanoprost Ophthalmic Solution
Drug
Lead sponsor
Santen Inc.
Industry
Eligibility
18 Years and older
Enrollment
241 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
12
States / cities
Artesia, California • Mission Hills, California • Newport Beach, California + 9 more
Source: ClinicalTrials.gov public record
Updated Oct 22, 2020 · Synced Sep 19, 2026, 11:50 AM EDT
Completed Phase 2 Interventional Results available

Tofacitinib Ointment For Chronic Plaque Psoriasis

NCT01831466
View directory record Official record
Conditions
Psoriasis Vulgaris, Psoriasis
Interventions
tofacitinib ointment 20 mg/g, tofacitinib ointment 10 mg/g, placebo ointment (vehicle)
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
476 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
29
States / cities
Hot Springs, Arkansas • Bakersfield, California • Irvine, California + 22 more
Source: ClinicalTrials.gov public record
Updated Nov 24, 2015 · Synced Sep 19, 2026, 11:50 AM EDT
Completed Phase 2 Interventional Results available

An 8-week Study to Evaluate Safety and Efficacy of NGF Eye Drops Solution Versus Vehicle in Patients With Dry Eye

NCT03019627
View directory record Official record
Conditions
Dry Eye
Interventions
NGF, Vehicle
Drug · Other
Lead sponsor
Dompé Farmaceutici S.p.A
Industry
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 7, 2019 · Synced Sep 19, 2026, 11:50 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Safety and Efficacy of ARQ-252 Cream in Subjects With Chronic Hand Eczema

NCT04378569
View directory record Official record
Conditions
Chronic Hand Eczema
Interventions
ARQ-252 cream 0.3%, ARQ-252 cream 0.1%, ARQ-252 Vehicle Cream
Drug
Lead sponsor
Arcutis Biotherapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
230 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
25
States / cities
Beverly Hills, California • Encino, California • Fremont, California + 21 more
Source: ClinicalTrials.gov public record
Updated Apr 4, 2024 · Synced Sep 19, 2026, 11:50 AM EDT
Completed Phase 2 Interventional

Study of ATI-1777 in Patients 12 to 65 Years Old With Mild to Severe Atopic Dermatitis

NCT05432596
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
ATI-1777 2.0% w/w, ATI-1777 1.0% w/w, ATI-1777 0.5% w/w, Vehicle
Drug
Lead sponsor
Aclaris Therapeutics, Inc.
Industry
Eligibility
12 Years to 65 Years
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
32
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Bryant, Arkansas + 29 more
Source: ClinicalTrials.gov public record
Updated Oct 25, 2024 · Synced Sep 19, 2026, 11:50 AM EDT
Completed Phase 2 Interventional Results available

Efficacy and Tolerability of Topical LFX453 for External Genital Warts

NCT02482428
View directory record Official record
Conditions
External Genital Warts
Interventions
Investigational Treatment, Aldara
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 60 Years · Male only
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Arlington Heights, Illinois
Source: ClinicalTrials.gov public record
Updated Jan 4, 2021 · Synced Sep 19, 2026, 11:50 AM EDT
Completed Phase 4 Interventional

The Long-Term Quitting (Smoking Cessation) Study

NCT02564315
View directory record Official record
Conditions
Smoking Cessation
Interventions
Nicotine Mini-Lozenge for 11 Months, Preparation Phase Behavioral Reduction Counseling, Preparation Phase Recycling Counseling, Preparation Phase Control Treatment, Cessation Phase Supportive Counseling, Cessation Phase Skill Training Counseling, Cessation Phase Brief Information, Cessation Phase Nicotine Patch + Nicotine Mini-Lozenge
Drug · Behavioral
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older
Enrollment
1,154 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Feb 16, 2020 · Synced Sep 19, 2026, 11:50 AM EDT
Completed Phase 2 Interventional

Clinical Study of ALLO-ASC-SHEET in Subjects with Diabetic Foot Ulcers

NCT03754465
View directory record Official record
Conditions
Diabetic Foot Ulcer
Interventions
ALLO-ASC-DFU, Hydrogel SHEET(Vehicle control)
Biological · Procedure
Lead sponsor
Anterogen Co., Ltd.
Industry
Eligibility
18 Years to 80 Years
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jan 22, 2025 · Synced Sep 19, 2026, 11:50 AM EDT